ABSTRACT
Background. Growing evidence supports the use of remdesivir and tocilizumab for the treatment of hospitalized patients with severe COVID-19. The purpose of this study was to evaluate the use of remdesivir and tocilizumab for the treatment of severe COVID-19 in a community hospital setting. Methods. We used a de-identified dataset of hospitalized adults with severe COVID-19 according to the National Institutes of Health definition (SpO2 < 94% on room air, a PaO2/FiO2 < 300 mm Hg, respiratory frequency > 30/min, or lung infiltrates > 50%) admitted to our community hospital located in Evanston Illinois, between March 1, 2020, and March 1, 2021. We performed a Cox proportional hazards regression model to examine the relationship between the use of remdesivir and tocilizumab and inpatient mortality. To minimize confounders, we adjusted for age, qSOFA score, noninvasive positive-pressure ventilation, invasive mechanical ventilation, and steroids, forcing these variables into the model. We implemented a sensitivity analysis calculating the E-value (with the lower confidence limit) for the obtained point estimates to assess the potential effect of unmeasured confounding. Figure 1. Kaplan-Meier survival curves for in-hospital death among patients treated with and without steroids The hazard ratio was derived from a bivariable Cox regression model. The survival curves were compared with a log-rank test, where a two-sided P value of less than 0.05 was considered statistically significant. Figure 2. Kaplan-Meier survival curves for in-hospital death among patients treated with and without remdesivir The hazard ratio was derived from a bivariable Cox regression model. The survival curves were compared with a log-rank test, where a two-sided P value of less than 0.05 was considered statistically significant. Results. A total of 549 patients were included. The median age was 69 years (interquartile range, 59 - 80 years), 333 (59.6%) were male, 231 were White (41.3%), and 235 (42%) were admitted from long-term care facilities. 394 (70.5%) received steroids, 192 (34.3%) received remdesivir, and 49 (8.8%) received tocilizumab. By the cutoff date for data analysis, 389 (69.6%) patients survived, and 170 (30.4%) had died. The bivariable Cox regression models showed decreased hazard of in-hospital death associated with the administration of steroids (Figure 1), remdesivir (Figure 2), and tocilizumab (Figure 3). This association persisted in the multivariable Cox regression controlling for other predictors (Figure 4). The E value for the multivariable Cox regression point estimates and the lower confidence intervals are shown in Table 1. The hazard ratio was derived from a bivariable Cox regression model. The survival curves were compared with a log-rank test, where a two-sided P value of less than 0.05 was considered statistically significant. The hazard ratios were derived from a multivariable Cox regression model adjusting for age as a continuous variable, qSOFA score, noninvasive positive-pressure ventilation, and invasive mechanical ventilation. Table 1. Sensitivity analysis of unmeasured confounding using E-values CI, confidence interval. Point estimate from multivariable Cox regression model. The E value is defined as the minimum strength of association on the risk ratio scale that an unmeasured confounder would need to have with both the exposure and the outcome, conditional on the measured covariates, to explain away a specific exposure-outcome association fully: i.e., a confounder not included in the multivariable Cox regression model associated with remdesivir or tocilizumab use and in-hospital death in patients with severe COVID-19 by a hazard ratio of 1.64-fold or 1.54-fold each, respectively, could explain away the lower confidence limit, but weaker confounding could not. Conclusion. For patients with severe COVID-19 admitted to our community hospital, the use of steroids, remdesivir, and tocilizumab were significantly associated with a slower progression to in-hospital death while controlling for other predictors included in the models.
ABSTRACT
Background: As the ongoing COVID-19 pandemic develops, there is a need for prediction rules to guide clinical decisions. Previous reports have identified risk factors using statistical inference model. The primary goal of these models is to characterize the relationship between variables and outcomes, not to make predictions. In contrast, the primary purpose of machine learning is obtaining a model that can make repeatable predictions. The objective of this study is to develop decision rules tailored to our patient population to predict ICU admissions and death in patients with COVID-19. Methods: We used a de-identified dataset of hospitalized adults with COVID- 19 admitted to our community hospital between March 2020 and June 2020. We used a Random Forest algorithm to build the prediction models for ICU admissions and death. Random Forest is one of the most powerful machine learning algorithms;it leverages the power of multiple decision trees, randomly created, for making decisions. Results: 313 patients were included;237 patients were used to train each model, 26 were used for testing, and 50 for validation. A total of 16 variables, selected according to their availability in the Emergency Department, were fit into the models. For the survival model, the combination of age >57 years, the presence of altered mental status, procalcitonin ≥3.0 ng/mL, a respiratory rate >22, and a blood urea nitrogen >32 mg/dL resulted in a decision rule with an accuracy of 98.7% in the training model, 73.1% in the testing model, and 70% in the validation model (Table 1, Figure 1). For the ICU admission model, the combination of age < 82 years, a systolic blood pressure of ≤94 mm Hg, oxygen saturation of ≤93%, a lactate dehydrogenase >591 IU/L, and a lactic acid >1.5 mmol/L resulted in a decision rule with an accuracy of 99.6% in the training model, 80.8% in the testing model, and 82% in the validation model (Table 2, Figure 2). Conclusion: We created decision rules using machine learning to predict ICU admission or death in patients with COVID-19. Although there are variables previously described with statistical inference, these decision rules are customized to our patient population;furthermore, we can continue to train the models fitting more data with new patients to create even more accurate prediction rules. (Table Presented).
ABSTRACT
SESSION TITLE: Late-breaking Abstract Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: October 18-21, 2020 PURPOSE: Coronavirus disease 2019 (COVID-19) is a new entity that has rapidly spread globally, claiming thousands of lives. Hydroxychloroquine, an agent used to prevent malaria and to treat autoimmune disorders, was being administered to COVID-19 cases to slow or prevent the disease. However, its use was rushed without sufficient evidence on efficacy and safety. METHODS: We retrospectively reviewed a de-identified dataset of 98 patients with COVID-19 admitted to a community hospital Intensive Care Unit (ICU) in Cook County, Illinois, from March 2020 to May 2020. Only confirmed COVID-19 cases, defined by a positive result on a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab were included. Co-infections were identified as the presence of positive blood cultures, sputum cultures, Legionella or pneumococcus urine antigen test, or respiratory viral panel. We performed a multivariable logistic regression analysis forcing variables that could be associated with increased risk of infection into the model, including central line placement, intubation, tocilizumab, intravenous steroids, colchicine, and hydroxychloroquine. RESULTS: Of 98 patients, the median age was 67 years (interquartile range, 57.75 – 74.25 years), 66 (67.3%) were males, 32 (32.7%) were Caucasian, and 56 (57.1%) were admitted from a Long-Term Care Facility (LTCF). 83.7% of the individuals had two or more comorbidities;the most frequent were hypertension (68.4%) and diabetes (51%). The most common targeted interventions included intravenous steroids (64.6%), azithromycin (42.9%), and hydroxychloroquine (34.7%). Among the group treated with hydroxychloroquine, 16 (47.1%) patients were found to have co-infections compared to 13 (20.3%) patients not treated with hydroxychloroquine (p=.006). The multivariable logistic regression showed increased odds of co-infection associated with the administration of hydroxychloroquine (odds ratio [OR] 4.04;95% CI 1.37 – 11.98, p=.012;Hosmer and Lemeshow goodness-of-fit test p=.724) and central line placement (OR 7.27;95% CI 1.93 – 27.31;p=.003). CONCLUSIONS: In this retrospective analysis of 98 adults with COVID-19 hospitalized in a community ICU, the patients who received hydroxychloroquine were found to have increased risk of co-infections. CLINICAL IMPLICATIONS: Hydroxychloroquine may increase the risk of co-infections in critical COVID-19 patients DISCLOSURES: No relevant relationships by Daniel Bustamante-Soliz, source=Web Response No relevant relationships by Chul Won Chung, source=Web Response No relevant relationships by Harvey Friedman, source=Web Response No relevant relationships by Elizabeth Patino, source=Web Response No relevant relationships by Guillermo Rodriguez-Nava, source=Web Response No relevant relationships by Daniela Trelles Garcia, source=Web Response No relevant relationships by Valeria Trelles Garcia, source=Web Response No relevant relationships by Maria Yanez-Bello, source=Web Response